Comprehensive training explores FDA oversight and current Good Tissue Practices (cGTPs) for professionals in the cell, gene therapy, and biologics industries. Our goal is to make the complex FDA ...

Please provide your email address to receive an email when new articles are posted on . A training course supports early-stage researchers in laboratory and translational science. The goal is to ...

Ahead of his talk at the 7th Annual Allogeneic Cell Therapies Summit, Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale ...

“Stem cell therapy and research are still effectively banned in South Africa,” Dr Mia said. “That hasn’t changed in law. What ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

When CAR T-therapies first reached the market, they came with warnings and monitoring requirements to protect patients — for good reason. Engineering a patient’s own immune cells into targeted cancer ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.